Design, synthesis and immunological evaluation of self-assembled antigenic peptides from dual-antigen targets : a broad-spectrum candidate for an effective antibreast cancer therapy
© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ..
BACKGROUND: Considering the narrow immune response spectrum of a single epitope, and the nanoparticles (NPs) as a novel adjuvant can achieve efficient delivery of antigenic peptides safely, a nano-system (denoted as DSPE-PEG-ManEM-NPs) based on cathepsin B-responsive antigenic peptides was designed and synthesized.
METHODS: Highly affinitive antigenic peptides were delivered by self-assembled NPs, and targeted erythrocyte membranes acted as a peptide carrier to improve antigenic peptides presentation and to strengthen cytotoxic T-cells reaction. Cathepsin B coupling could release antigenic peptides rapidly in dendritic cells.
RESULTS: Evaluations showed that DSPE-PEG-ManEM-NPs had obvious inhibitory effects towards both MCF-7 and MDA-MB-231 human breast cancer cell lines.
CONCLUSION: Overall, this strategy provides a novel strategy for boosting cytotoxic T lymphocytes response, thereby expanding the adaptation range of tumor antigenic peptides and improving the therapeutic effect of tumor immunotherapy with nanomedicine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Journal for immunotherapy of cancer - 9(2021), 6 vom: 03. Juni |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shi, Wei [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.12.2021 Date Revised 20.12.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1136/jitc-2021-002523 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM326317570 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM326317570 | ||
| 003 | DE-627 | ||
| 005 | 20231225194331.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/jitc-2021-002523 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1087.xml |
| 035 | |a (DE-627)NLM326317570 | ||
| 035 | |a (NLM)34083420 | ||
| 035 | |a (PII)e002523 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shi, Wei |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Design, synthesis and immunological evaluation of self-assembled antigenic peptides from dual-antigen targets |b a broad-spectrum candidate for an effective antibreast cancer therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.12.2021 | ||
| 500 | |a Date Revised 20.12.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. | ||
| 520 | |a BACKGROUND: Considering the narrow immune response spectrum of a single epitope, and the nanoparticles (NPs) as a novel adjuvant can achieve efficient delivery of antigenic peptides safely, a nano-system (denoted as DSPE-PEG-ManEM-NPs) based on cathepsin B-responsive antigenic peptides was designed and synthesized | ||
| 520 | |a METHODS: Highly affinitive antigenic peptides were delivered by self-assembled NPs, and targeted erythrocyte membranes acted as a peptide carrier to improve antigenic peptides presentation and to strengthen cytotoxic T-cells reaction. Cathepsin B coupling could release antigenic peptides rapidly in dendritic cells | ||
| 520 | |a RESULTS: Evaluations showed that DSPE-PEG-ManEM-NPs had obvious inhibitory effects towards both MCF-7 and MDA-MB-231 human breast cancer cell lines | ||
| 520 | |a CONCLUSION: Overall, this strategy provides a novel strategy for boosting cytotoxic T lymphocytes response, thereby expanding the adaptation range of tumor antigenic peptides and improving the therapeutic effect of tumor immunotherapy with nanomedicine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a CD8-positive t-lymphocytes | |
| 650 | 4 | |a antigen presentation | |
| 650 | 4 | |a immunogenicity | |
| 650 | 4 | |a immunotherapy | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Antibodies, Bispecific |2 NLM | |
| 650 | 7 | |a HLA-A2 Antigen |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 650 | 7 | |a Phosphatidylethanolamines |2 NLM | |
| 650 | 7 | |a polyethylene glycol-distearoylphosphatidylethanolamine |2 NLM | |
| 650 | 7 | |a Polyethylene Glycols |2 NLM | |
| 650 | 7 | |a 3WJQ0SDW1A |2 NLM | |
| 650 | 7 | |a CTSB protein, human |2 NLM | |
| 650 | 7 | |a EC 3.4.22.1 |2 NLM | |
| 650 | 7 | |a Cathepsin B |2 NLM | |
| 650 | 7 | |a EC 3.4.22.1 |2 NLM | |
| 700 | 1 | |a Qiu, Qianqian |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Ziying |e verfasserin |4 aut | |
| 700 | 1 | |a Tong, Zhenzhen |e verfasserin |4 aut | |
| 700 | 1 | |a Guo, Weiwei |e verfasserin |4 aut | |
| 700 | 1 | |a Zou, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Yue, Na |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Wenlong |e verfasserin |4 aut | |
| 700 | 1 | |a Qian, Hai |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal for immunotherapy of cancer |d 2013 |g 9(2021), 6 vom: 03. Juni |w (DE-627)NLM23381065X |x 2051-1426 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2021 |g number:6 |g day:03 |g month:06 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/jitc-2021-002523 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2021 |e 6 |b 03 |c 06 | ||